AN2 Therapeutics, Inc. (ANTX)
USD 1.31
(-2.24%)
USD 1.31
(-2.24%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -53.28 Million | -33.46 Million | -20.48 Million | -5.36 Million | -2.48 Million |
| Net Income | -64.73 Million | -40.95 Million | -21.54 Million | -13.6 Million | -5.63 Million |
| Depreciation & Amortization | - | -692 Thousand | - | - | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 8.41 Million | 4.39 Million | 974 Thousand | 40 Thousand | - |
| Change in working capital | 5.83 Million | 3.71 Million | 32 Thousand | 1.22 Million | -10 Thousand |
| Other non-cash items | -2.8 Million | 77 Thousand | 53 Thousand | 6.97 Million | 3.17 Million |
| Investing Cash Flow | -43.27 Million | -21.77 Million | -50.02 Million | - | - |
| Investments in PPE | - | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -132.17 Million | -93.83 Million | -77.27 Million | - | - |
| Sales/Maturities of investments | 88.9 Million | 72.06 Million | 27.25 Million | - | - |
| Other Investing Activities | -43.27 Thousand | -21.77 Thousand | -50.02 Thousand | - | - |
| Financing Cash Flow | 84.99 Million | 70.35 Million | 78.53 Million | 3.83 Million | 8.08 Million |
| Debt repayment | - | -11 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | -11 Thousand | - | - | - |
| Common Stock Issuance | 84.99 Million | 70.36 Million | 78.53 Million | 3.83 Million | 8.08 Million |
| Other Financing Activities | 19.51 Million | 1.83 Million | -1.21 Million | 3836.00 | 48.5 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | 553 Thousand | 2.49 Million | 417 Thousand | 81 Thousand | -16 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | 5.28 Million | 1.22 Million | -385 Thousand | 1.14 Million | 6000.00 |
| Cash at beginning of period | 27.21 Million | 12.09 Million | 4.07 Million | 5.59 Million | - |
| Cash at end of period | 15.64 Million | 27.21 Million | 12.09 Million | 4.07 Million | 5.59 Million |
| Capital Expenditure | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -11.57 Million | 15.12 Million | 8.02 Million | -1.52 Million | 5.59 Million |
| Free Cash Flow | -53.28 Million | -33.46 Million | -20.48 Million | -5.36 Million | -2.48 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -14.43 Million | -16.61 Million | -16.89 Million | -64.73 Million | -16.7 Million | -15.8 Million |
| Depreciation & Amortization | - | - | 414 Thousand | - | - | 21 Thousand |
| Deferred income taxes | - | - | 21 Thousand | - | - | -21 Thousand |
| Stock-based compensation | 2.27 Million | 2.38 Million | 2.23 Million | 8.41 Million | 2.16 Million | 1.94 Million |
| Change in working capital | -1.33 Million | -2.27 Million | -1.09 Million | 5.83 Million | 3.37 Million | 1.47 Million |
| Other non-cash items | 1.92 Million | 1.53 Million | -1.3 Million | -2.8 Million | -640 Thousand | -440 Thousand |
| Investing Cash Flow | 16.46 Million | 26.29 Million | 420 Thousand | -43.27 Million | -62.46 Million | 7.87 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -12.59 Million | - | -19.83 Million | -132.17 Million | -85.21 Million | -13.12 Million |
| Sales/Maturities of investments | 29.05 Million | 26.29 Million | 20.25 Million | 88.9 Million | 22.75 Million | 21 Million |
| Other Investing Activities | 16.46 Million | 26.29 Million | 420.00 | -43.27 Thousand | -62.46 Thousand | 7877.00 |
| Financing Cash Flow | - | 349 Thousand | -321 Thousand | 84.99 Million | 66.06 Million | 19.05 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -321.00 | - | - | - |
| Common Stock Issuance | - | 349 Thousand | -321 Thousand | 84.99 Million | 65.8 Million | 19.05 Million |
| Other Financing Activities | - | 225 Thousand | 19.24 Million | 19.51 Million | 266 Thousand | 19.05 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -548 Thousand | -243 Thousand | -2.1 Million | 553 Thousand | 1.65 Million | -414 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -782 Thousand | -2.02 Million | 1.01 Million | 5.28 Million | 1.72 Million | 1.89 Million |
| Cash at beginning of period | 24.69 Million | 15.64 Million | 32.61 Million | 27.21 Million | 40.81 Million | 26.7 Million |
| Cash at end of period | 26.76 Million | 24.69 Million | 15.64 Million | 15.64 Million | 32.61 Million | 40.81 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 2.07 Million | 9.04 Million | -16.96 Million | -11.57 Million | -8.19 Million | 14.1 Million |
| Free Cash Flow | -14.38 Million | -17.59 Million | -17.06 Million | -53.28 Million | -11.8 Million | -12.82 Million |
098460
STGX
603909
LCUT
KITT
011200